Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States

Urology

Volumn 97, Issue , 2016, Pages 111-117

  Kim, Simon P ^a,b,c   Karnes, R Jeffrey ^d   Gross, Cary P ^c,e   Meropol, Neal J ^b   Van Houten, Holly ^d   Abouassaly, Robert ^a,b   Shah, Nilay D ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c YALE UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; COHORT ANALYSIS; COMORBIDITY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL GEOGRAPHY; MEDICAL SOCIETY; MIDDLE AGED; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROSTATE CANCER; RACE; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES; ANCESTRY GROUP; BLOOD; EARLY CANCER DIAGNOSIS; ECONOMICS; FACTUAL DATABASE; INSURANCE; PRIVATE SECTOR; PROCEDURES; PROSTATE TUMOR; RISK ASSESSMENT; TRENDS; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DATABASES, FACTUAL; EARLY DETECTION OF CANCER; HUMANS; INSURANCE COVERAGE; MALE; MIDDLE AGED; PRIVATE SECTOR; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES;

EID: 85007372141     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2016.06.067     Document Type: Article

References (30)

1. 1 Schroder, F.H., Hugosson, J., Roobol, M.J., et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366 (2012), 981–990.
2. 2 Schroder, F.H., Hugosson, J., Roobol, M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009), 1320–1328.
3. 3 Andriole, G.L., Crawford, E.D., Grubb, R.L. 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009), 1310–1319.
4. 4 Moyer, V.A., Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157 (2012), 120–134.
5. 5 Kawachi, M.H., Bahnson, R.R., Barry, M., et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 8 (2010), 240–262.
6. 6 Carter, H.B., Albertsen, P.C., Barry, M.J., et al. Early detection of prostate cancer: AUA guideline. J Urol 190:2 (2013), 419–426.
7. 7 Wolf, A.M., Wender, R.C., Etzioni, R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update. CA Cancer J Clin 60 (2010), 70–98.
8. 8 Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
9. 9 Cooperberg, M.R., Broering, J.M., Carroll, P.R., Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28 (2010), 1117–1123.
10. 10 Jacobs, B.L., Zhang, Y., Schroeck, F.R., et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA 309 (2013), 2587–2595.
11. 11 Kim, S.P., Shah, N.D., Karnes, R.J., et al. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol 64 (2013), 11–16.
12. 12 Nguyen, P.L., Gu, X., Lipsitz, S.R., et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29 (2011), 1517–1524.
13. 13 Ross, J.S., Wang, R., Long, J.B., Gross, C.P., Ma, X., Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med 172 (2012), 1601–1603.
14. 14 Li, J., Berkowitz, Z., Hall, I.J., Decrease in prostate cancer testing following the US preventive services task force (USPSTF) recommendations. J Am Board Fam Med 28 (2015), 491–493.
15. 15 Jemal, A., Fedewa, S.A., Ma, J., et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 314 (2015), 2054–2061.
16. 16 Etzioni, R., Gulati, R., Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA Oncol 2 (2016), 955–956.
17. 17 Ma, X., Wang, R., Long, J.B., et al. The cost implications of prostate cancer screening in the Medicare population. Cancer 120 (2014), 96–102.
18. 18 Welch, H.G., Albertsen, P.C., Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101 (2009), 1325–1329.
19. 19 Kim, S.P., Shah, N.D., Karnes, R.J., et al. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol 64 (2012), 11–16.
20. 20 Wallace, P.J., Shah, N.D., Dennen, T., Bleicher, P.A., Crown, W.H., Optum Labs: building a novel node in the learning health care system. Health Aff 33 (2014), 1187–1194.
21. 21 Walter, L.C., Bertenthal, D., Lindquist, K., Konety, B.R., PSA screening among elderly men with limited life expectancies. JAMA 296 (2006), 2336–2342.
22. 22 Deyo, R.A., Cherkin, D.C., Ciol, M.A., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992), 613–619.
23. 23 Chou, R., Croswell, J.M., Dana, T., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155 (2011), 762–771.
24. 24 Zeliadt, S.B., Hoffman, R.M., Etzioni, R., Gore, J.L., Kessler, L.G., Lin, D.W., Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 103 (2011), 520–523.
25. 25 Force USPST, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149 (2008), 185–191.
26. 26 Drazer, M.W., Prasad, S.M., Huo, D., et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer 120 (2014), 1491–1498.
27. 27 Bill-Axelson, A., Holmberg, L., Ruutu, M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364 (2011), 1708–1717.
28. 28 Bill-Axelson, A., Holmberg, L., Ruutu, M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005), 1977–1984.
29. 29 Prasad, S.M., Drazer, M.W., Huo, D., Hu, J.C., Eggener, S.E., 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 307 (2012), 1692–1694.
30. 30 Ross, J.S., Wang, R., Long, J.B., Gross, C.P., Ma, X., Impact of the 2008 US preventive services task force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med, 2012, 1–3.